RE: Stunning update4 Sep 2025 10:22
Nice news today !!!! GLA
Thomas Guiel, COO of Oxford BioDynamics, said: "The PROWES results represent a significant milestone that further validates the transformative real-world impact of the EpiSwitch CiRT test on decision-making in real clinical practice.
"These results not only strengthen the scientific foundation of CiRT, but also support our strategy to secure inclusion in NCCN (National Comprehensive Cancer Network) clinical guidelines. The Company expects to apply for inclusion later this year, which is a critical step towards driving widespread adoption and achieving our commercial objectives."